The AnkyrBio technology enables therapeutics to be administered in eye drops and remain active on the surface of the eye for up to 3-5 days. This unique technology localizes the therapeutics to the site of the application, extends the drug duration of action, reduces dosing requirements and minimizes systemic toxicity.